← Back to Cagrilintide product page
Biblioteca de investigación
Published research on this compound — for educational purposes only
What is Cagrilintide’s amylin receptor pharmacology? (for educational purposes only)
Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA) that binds to amylin receptor subtypes AMY1R, AMY2R, and AMY3R, as well as the calcitonin receptor (CTR). Amylin receptors are heterodimeric complexes formed by the calcitonin receptor (CTR) co-expressed with receptor activity-modifying proteins (RAMPs 1-3). Cagrilintide demonstrates nanomolar potency at these receptor complexes in cAMP accumulation assays. The compound’s broad amylin receptor engagement profile — activating all three AMY subtypes — provides a distinct signaling signature compared to native amylin, which shows preferential AMY1R and AMY3R activity. For laboratory research use only.
Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of Cagrilintide by amylin receptors.” Nat Commun. 2025;16:1234. PubMed
How is Cagrilintide classified as an amylin analog? (for educational purposes only)
Cagrilintide is an amylin analog. It acts through amylin and calcitonin receptor signaling pathways. Amylin receptors are concentrated in the area postrema and other hindbrain regions in research models. Cagrilintide has no meaningful affinity for incretin or glucagon receptor families in the published binding work cited here. For laboratory research use only.
Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of Cagrilintide by amylin receptors.” Nat Commun. 2025;16:1234. PubMed
What is the structural basis for Cagrilintide’s extended duration of action? (for educational purposes only)
Native human amylin (37 amino acids) has a circulating half-life of approximately 13 minutes due to rapid renal clearance and enzymatic degradation. Cagrilintide overcomes this through N-terminal lipidation with a C-18 fatty diacid moiety, enabling high-affinity non-covalent binding to serum albumin. This albumin association creates a circulating reservoir, extending the pharmacokinetic half-life to approximately 7 days. Additional modifications include amino acid substitutions that confer resistance to amidase and protease degradation while preserving receptor binding geometry. Cryo-EM structural studies have elucidated how Cagrilintide maintains receptor engagement despite these modifications. For laboratory research use only.
Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of Cagrilintide by amylin receptors.” Nat Commun. 2025;16:1234. PubMed
What is the research context for Cagrilintide in combination studies? (for educational purposes only)
Because Cagrilintide engages amylin/calcitonin receptors, it has been investigated alongside other receptor-selective research ligands. The AMY1-3R/CTR targets engage distinct downstream signaling pathways, providing a rationale for combination investigation in controlled laboratory models. Preclinical receptor binding studies are used to confirm whether ligands compete at the same receptor complexes. For laboratory research use only.
Citation: Cao C, Yang K, Liu S, et al. “Structural basis for the recognition of Cagrilintide by amylin receptors.” Nat Commun. 2025;16:1234. PubMed
Continue reviewing Cagrilintide
Use the research references above alongside Panda’s batch documentation and catalog specifications.
Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.